-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

625.P1.27 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
ALL, antibodies, apoptosis, Biological, Follicular Lymphoma, Leukemia, multiple myeloma, cell division, CLL, Diseases, Lymphoma (any), Marginal Zone Lymphoma, Non-Biological, CAR-Ts, cell regulation, Combinations, Mantle Cell Lymphoma, Therapies, chemotherapy, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Biological Processes, DLBCL, DNA damage, enzyme inhibitors, DNA repair, T-Cell Lymphoma, immunotherapy, Xenograft models, Lymphoid Malignancies, Study Population, pharmacology, inflammation, pathogenesis, pathways, signal transduction
Saturday, December 5, 2020: 7:00 AM-3:30 PM

Jie Wang, MD, MS1, Katarzyna Urbanska, PhD2*, Prannda Sharma3*, Mathilde Poussin3*, Reza Nejati, MD4*, Lauren Shaw3*, Megan S. Lim, MD, PhD5, Stephen J. Schuster, MD5 and Daniel Powell Jr., PhD6*

1Duke University, Durham, NC
2Bristol-Meyers Squibb, Philadelphia, PA
3University of Pennsylvania, Philadelphia, PA
4Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA
5Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
6Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA

Elana Thieme, BS1*, Vi Lam1*, Nur Bruss, BS1*, Fei Xu1*, Stephen E Kurtz, PhD2*, Jeffrey W. Tyner, PhD3, Alexey Danilov, MD4 and Tingting Liu1*

1Oregon Health and Science University, Portland, OR
2Knight Cancer Institute, Mail code: KR-HEM, Oregon Health & Science University, Portland, OR
3Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR
4Knight Cancer Institute, Oregon Health & Science University, Portland, OR

Wu Yin, PhD1, Nie Zhe, PhD2*, Andrew Placzek, PhD1*, Michael Trzoss, PhD3*, Goran Krilov, PhD1*, Shulu Feng, PhD4*, Morgan Lawrenz, PhD5*, Robert Pelletier, PhD3*, George Lai, PhD6*, Jeff Bell, PhD3*, David Calkins3*, Mary Grimes3*, Wayne Tang, PhD3*, Fiona McRobb, PhD5*, Aleksey Gerasyuto, PhD5*, Victoria Feher, PhD3*, Sayan Mondal, PhD4*, Kristian Jensen, PhD3*, Hamish Wright, PhD3* and Karen Akinsanya, PhD4*

1Schrodinger, New York, NY
2Schrodinger, New York, NJ
3Schrodinger, New York
4schrodinger, New york
5Schrodinger, New york
6Triplet Therapeutics, Boston

Juan J Gu, MD, PhD1,2*, Cory Mavis, MSc1,2*, Pallawi Torka, MD1*, Suchitra Sundaram, MD1* and Francisco J. Hernandez-Ilizaliturri, MD2,3

1Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
2Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY
3Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY

Asma Jabeen, PhD1*, Shiran Huang2*, John A. Hartley, PhD2*, Patrick H Van Berkel, PhD1* and Francesca Zammarchi, PhD1*

1ADC Therapeutics (UK) Limited, London, ENG, United Kingdom
2UCL Cancer Institute, London, United Kingdom

Eliana B. Gomez, PhD1*, Wenjuan Wu, PhD2*, Jennifer R Stephens, BS2*, Mary S. Rosendahl, PhD1* and Barbara J. Brandhuber, PhD1*

1Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Boulder, CO
2Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN

Tingting Liu1*, Fei Xu2*, Elana Thieme, BS1*, Vi Lam3*, Guang Fan, MD, PhD4, Liana Nikolaenko, MD5, Stephen E Kurtz, PhD6*, Jeffrey W. Tyner, PhD7, Olga Danilova1* and Alexey Danilov, MD8

1City of Hope, Duarte, CA
2Oregon Health and Science University, Portland, OR
3City Of Hope, Duarte, CA
4Department of Pathology, Oregon Health and Science University, Portland, OR
5Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA
6Knight Cancer Institute, Mail code: KR-HEM, Oregon Health & Science University, Portland, OR
7Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR
8Toni Stephenson Lymphoma Center, City of Hope Comprehensive Cancer Center, Duarte, CA

Yuxuan Che1*, Yang Liu, PhD1*, Lingzhi Li1*, Holly Hill1*, Joseph McIntosh, BS1*, Alexa A Jordan, BS1*, Dayoung Jung1*, Yixin Yao, PhD1, Vivian Changying Jiang, PhD1 and Michael Wang, MD1,2

1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

*signifies non-member of ASH